TICKERNERD
Menu
AMGNAMGNHealthcare · Drug Manufacturers - General

AMGN Stock Forecast: Amgen, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$377
−1.34% on the day

The 34 Wall Street analysts covering Amgen, Inc. hold a median 12-month price target of $395 — +4.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 12 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$204.0B
Ticker Nerd rank
90 / 100
Median analyst target
$395
Analysts covering
34
Revenue$10.1B+9.5% y/y
Operating income$3.5B
Net income$2.4B
Free cash flow$3.5B
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−15.0%
1M
−8.4%
YTD
+17.7%
1Y
+37.2%
From 52W high
−15.0%
From 52W low
+43.1%
$264
$444
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AMGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Amgen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
90 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
98
Quality
96
Value
91
Revisions
87
Momentum
75
Growth
67
Accruals
55
Issuance
46
Size
1

Volatility (98): The share price has been relatively steady.

Issuance (46): The company has been issuing shares or taking on financing, diluting existing holders.

Size (1): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AMGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AMGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$200$250$300$350$400$450Oct 25Jan 26Apr 26Jul 26AMGNHigh $457Median $395Low $225

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says34 analysts
12 Buy18 Hold4 Sell
Low $225Median $395High $457

The green dot is the last close — the median target sits +4.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
10 Sept 2026HSBCDowngradeHold$445 → $425
8 Sept 2026BMO CapitalDowngradeMarket Perform$450
8 Sept 2026Cantor FitzgeraldReiteratesNeutral$400
4 Sept 2026Wells FargoMaintainsEqual-Weight$400 → $435
20 Aug 2026Piper SandlerMaintainsOverweight$427 → $457
20 Aug 2026Piper SandlerMaintainsOverweight—
19 Aug 2026Argus ResearchMaintainsBuy—
19 Aug 2026Argus ResearchMaintainsBuy$375 → $460
19 Aug 2026Morgan StanleyMaintainsEqual-Weight$351 → $362
19 Aug 2026Morgan StanleyMaintainsEqual-Weight—
18 Aug 2026Cantor FitzgeraldMaintainsNeutral$350 → $400
18 Aug 2026Cantor FitzgeraldMaintainsNeutral—
18 Aug 2026MizuhoMaintainsNeutral—
18 Aug 2026MizuhoMaintainsNeutral$303 → $352
14 Aug 2026BarclaysMaintainsEqual-Weight$360 → $380
14 Aug 2026BarclaysMaintainsEqual-Weight—
10 Aug 2026GuggenheimMaintainsNeutral—
10 Aug 2026GuggenheimMaintainsNeutral$343 → $388
7 Aug 2026CitigroupMaintainsNeutral—
7 Aug 2026CitigroupMaintainsNeutral$345 → $405

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AMGN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

AMGN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Amgen, Inc. returned +37.2% against +17.5% for the S&P 500, dividends included.

AMGN vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160Oct 25Jan 26Apr 26Jul 26AMGNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AMGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+2.8%
Analysts raising
32
Analysts cutting
0
Fundamentals

Amgen, Inc. (AMGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
23.4×

Cheaper than 32% of US stocks

Price / sales
5.4×

Cheaper than 23% of US stocks

Price / book
17.5×

Cheaper than 5% of US stocks

EV / EBITDA
14.3×

Cheaper than 24% of US stocks

Growth & margins
Revenue growth (YoY)
9.5%

Higher than 51% of US stocks

Earnings growth (YoY)
65.9%

Higher than 79% of US stocks

Gross margin
72.0%

Higher than 84% of US stocks

Operating margin
35.5%

Higher than 90% of US stocks

Net margin
23.0%

Higher than 84% of US stocks

Returns & dividend
Return on equity
91.5%

Higher than 96% of US stocks

Return on assets
8.7%

Higher than 90% of US stocks

Dividend yield
2.7%

Higher than 58% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Amgen, Inc. (AMGN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Amgen, Inc. has a market value of $204.0B and an enterprise value of $247.3B.

  • Revenue in the twelve months to 30 June 2026: $38.1B. The latest quarter grew 9.5% year on year.

  • Net income over the same four quarters: $8.7B, a 23.0% net margin.

  • Diluted earnings per share, trailing twelve months: $16.09.

  • Free cash flow in the twelve months to 30 June 2026: $10.2B.

  • Amgen, Inc. spent $5.3B on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 540.6M.

  • Trailing P/E: 23.4×; forward P/E: 15.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 2.67%, paying out 61% of earnings.

  • Amgen, Inc. employs 31,500 people — $1.2M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

AMGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
AMGNAmgen, Inc.$204.0B
90
GILDGilead Sciences, Inc.$178.4B
93
PFEPfizer Inc.$157.6B
78
BMYBristol Myers Squibb Co.$129.6B
99
MRKMerck & Co., Inc.$357.2B
82
ABBVAbbVie, Inc.$454.3B
96
JNJJohnson & Johnson$640.0B
91

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Amgen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AMGN news & analysis

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool · 14 Sept 2026neutral

A Motley Fool article compares Amgen and Vertex Pharmaceuticals as healthcare stock picks for 2026. It notes Amgen maintains a massive, diversified portfolio of medicines serving approximately 17 million patients globally, while Vertex dominates the cystic fibrosis market with high net margins and a pristine balance sheet.

Why it matters — The piece highlights Amgen's scale and broad, diversified medicine portfolio, offering AMGN watchers a factual basis for comparing its position against a leading competitor.

Amgen Highlights 26% Growth Drivers, IMDELLTRA Momentum and MariTide Potential

MarketBeat · 11 Sept 2026positive

Amgen executives highlighted growth across its key commercial products, progress in its late-stage development programs, and a continued focus on profitability and cash returns during a Wells Fargo biotech and pharma discussion. The company emphasized momentum for IMDELLTRA and the potential of MariTide.

Why it matters — Amgen watchers would care because the commentary signals continued strength in the company's commercial portfolio and promising late-stage pipeline programs.

Amgen Drops 10% on a Trial It Didn't Even Run

MarketBeat · 11 Sept 2026neutral

Amgen's stock dropped 10% following a trial result that the company did not conduct. The decline came despite Amgen delivering a strong earnings report on Aug. 4.

Why it matters — AMGN watchers would care because a 10% share-price drop tied to an external trial outcome could affect the stock's valuation and investor perception even though Amgen was not involved in running the trial.

Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool · 11 Sept 2026neutral

The Motley Fool compares Amgen and clinical-stage oncology specialist Revolution Medicines as potential healthcare investments for 2026. It notes Amgen's large global footprint and over $8.1 billion in free cash flow generated in its latest fiscal year, while Revolution Medicines focuses on high-stakes RAS-addicted cancer therapies.

Why it matters — The piece highlights Amgen's strong free cash flow and global scale, which are relevant context for investors tracking Amgen's financial strength and competitive position.

Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool · 11 Sept 2026positive

The Motley Fool compares Amgen and CRISPR Therapeutics as potential healthcare investments for 2026, noting that Amgen offers a stable foundation with multi-billion dollar revenues and consistent cash flows, while CRISPR Therapeutics presents high growth potential through its gene-editing technology.

Why it matters — For AMGN watchers, this piece highlights Amgen's financial stability and reliable cash generation as key attributes relative to a higher-risk, higher-growth peer.

FAQ

Frequently asked questions about AMGN stock

What is the AMGN stock price forecast for 2026-2027?

The 34 Wall Street analysts covering Amgen, Inc. have a median 12-month price target of $395, with estimates ranging from $225 to $457. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AMGN stock a buy right now?

Of the 34 analysts covering Amgen, Inc., 12 rate it a Buy, 18 a Hold and 4 a Sell. Ticker Nerd's systematic factor model ranks Amgen, Inc. 90 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AMGN?

As at 12 Sept 2026, Amgen, Inc. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).

Will AMGN stock go up?

No one can know that. What the data says: the median 12-month target from 34 analysts implies +4.7% from the last close, and Ticker Nerd's factor model ranks Amgen, Inc. 90 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AMGN stock forecast for 2030?

No analyst covering Amgen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AMGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $225 to $457 over the next 12 months.

How has AMGN stock performed over the past year?

Amgen, Inc. returned +37.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Amgen, Inc. do?

Amgen Inc. is a global biotechnology company that discovers, develops, manufactures, and commercializes human therapeutics.

What is the latest news on AMGN?

The most recent item we track (The Motley Fool, 14 Sept 2026): "Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?". A Motley Fool article compares Amgen and Vertex Pharmaceuticals as healthcare stock picks for 2026. It notes Amgen maintains a massive, diversified portfolio of medicines serving approximately 17 million patients globally, while Vertex dominates the cystic fibrosis market with high net margins and a pristine balance sheet.

Company

About Amgen, Inc.

Amgen Inc. is a global biotechnology company that discovers, develops, manufactures, and commercializes human therapeutics. Its current portfolio focuses on serious diseases across oncology, cardiovascular disease, inflammation, bone health, nephrology, and rare diseases, with medicines delivered through biologics such as recombinant proteins and monoclonal antibodies. Amgen works with healthcare providers, hospitals, pharmacies, and wholesalers, serving patients in developed markets worldwide. The company’s role in the financial market is closely tied to its branded biologic medicines and research-driven product pipeline, which support its position as one of the leading independent biotechnology companies. Headquartered in Thousand Oaks, California, Amgen combines large-scale manufacturing and global distribution with a strong emphasis on innovative treatments for conditions with high unmet medical need.

CEO Mr. Robert A. Bradway · 31,500 employees · United States · https://www.amgen.com